EN DE
Watch Micro-X Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Micro-X Ltd (MX1) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Micro-X Ltd stock A$0.03, price A$0.03, upside +3.1%, quality 30 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU000000MX15

MX Micro-X Ltd logo Thin data Nov 13, 2026

Micro-X Ltd

MX1 · AU

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Fair value A$0.0289 · Fairly valued 
Mixed Growth (revenue 5y +32.0 %/yr in AUD) 
Revenue last quarter 32% below a year ago. 
Quality 30/100 
Falling price (downtrend) 
Loss-making · -65.5% net margin (TTM) 
Negative free cash flow 
Trails peers (3/9) 
Narrow moat 9/100
Thin data 
Estimate
Watch Micro-X Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.3400 A$0.0140 Fair Value A$0.0289 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range A$0.0140 – A$0.3400 · fair‑value band A$0.0269 – A$0.0308 · the A$0.0280 price screens below the A$0.0289 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 13, 2026.

Follow Micro-X in your weekly email

Every Wednesday you see whether Micro-X is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Micro-X Limited designs, develops, manufactures, and commercializes imaging products for healthcare, defense, and security markets through cold cathode X-ray technology. The company provides carbon nanotube-based X-ray products, including core X-ray tube and high-voltage generator components.

Show moreShow less

It also provides Rover Plus for medical performance in a mobile system; Head CT, a standard ambulance or retrieval aircraft for stroke; Checkpoints, a modular passenger self-screening checkpoint for airports; Baggage scanner, a CT baggage scanner for passenger self-screening checkpoints; Argus, a wide-area scattered projection backscatter and miniaturized high-voltage generator; and space imaging solutions.

The company operates in Australia, the United States, the Asia-Pacific, Europe, the Middle East, and Africa. Micro-X Limited was incorporated in 2011 and is based in Tonsley, Australia.

Stock analysis

Micro-X Ltd (MX1) currently trades at A$0.0280, while our estimate is A$0.0289, so the stock looks roughly fairly valued today (gap 3.0%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0269 (bear) to A$0.0308 (bull), the price of A$0.0280 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Micro-X Ltd reported revenue of A$15.1M in FY2026 versus A$9.0M in FY2022, a compound +13.9%/yr. Reported net income was −A$9.9M in FY2026.

Key figures

Market cap A$21.1M (≈ $14.3M) Micro · P/S ratio 1.80 · EPS (TTM) A$−0.0100 · Net margin −65.5% · Return on equity −158% · Return on assets (EBIT) −64.5% (5-year average) · Operating margin −312% · Revenue (TTM) A$15.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 73% below its 52-week high and 100% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at 3%, MX1 screens richer than that median.

Fair Value

Bear A$0.0269 Fair Value A$0.0289 Bull A$0.0308
Price A$0.0280 · Upside +3.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 54
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 37
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+15.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.0%
Start year 2021 (pandemic). Over 10 years: +32.7% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−419.8% (2021) → −104.7% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch MX1, get fair value alerts →

Compare Micro-X Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside +3.2% · Above median
Profitability
Return on assets −50.1% · Bottom 25%
Net margin (12 months) −65.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −32.0% · Bottom 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 4.29× · Priciest 25%
P/S (12 months) 1.40× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)38 · sector 17
FUTURE (revenue growth)0 · sector 41
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $309.64 $343.63 +11% vs MX1
Boston Scientific Corporation BSX $44.34 $48.77 +10% vs MX1
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥179.40 ¥197.34 +10% vs MX1
DexCom, Inc DXCM $83.33 $91.66 +10% vs MX1
STERIS plc STE $264.32 $281.90 +7% vs MX1
GE HealthCare Technologies Inc GEHC $83.02 $69.92 −16% vs MX1
Edwards Lifesciences Corporation EW $107.15 $81.94 −24% vs MX1
Medtronic plc MDT $102.86 $74.90 −27% vs MX1
Abbott Laboratories, ABT $108.52 $75.28 −31% vs MX1
Koninklijke Philips N.V PHIA €27.43 €15.23 −44% vs MX1

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Micro-X Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Micro-X Ltd Fair Value". https://www.fairvalue-calculator.com/stock/MX1

Frequently asked questions

Is Micro-X Ltd (MX1) overvalued or undervalued?
As of Nov 13, 2026, our estimate of fair value is A$0.0289 versus a price of A$0.0280, about +3% upside (fairly valued).
What is the fair value of MX1?
Our estimate for Micro-X Ltd is A$0.0289 (as of Nov 13, 2026), built from audited fundamentals. The current price: A$0.0280.
What is the quality score of MX1?
Micro-X Ltd has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Micro-X Ltd (MX1)?
Our calculated price target is the estimate of A$0.0289 (as of Nov 13, 2026). Cautious scenario A$0.0269, optimistic scenario A$0.0308. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Micro-X Ltd stock forecast for 2026?
Our estimate puts fair value at A$0.0289, about +3% upside versus a price of A$0.0280 (fairly valued). Cautious scenario A$0.0269, optimistic scenario A$0.0308. The calculation is refreshed regularly with new filings.
What is the revenue of Micro-X Ltd (MX1)?
Micro-X Ltd reported trailing-twelve-month revenue of about A$15.1M (latest available figure, as of Nov 13, 2026).
What is the intrinsic value of Micro-X Ltd (MX1)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Micro-X Ltd it is A$0.0289 per share (as of Nov 13, 2026), against a price of A$0.0280.
Is Micro-X Ltd stock overvalued or undervalued in 2026?
As of Nov 13, 2026, MX1 trades below its calculated fair value: price A$0.0280, fair value A$0.0289, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MX1?
No. The price is what the market pays today (A$0.0280); the fair value is what the company's own numbers justify (A$0.0289). For Micro-X Ltd the two are A$0.0009 per share apart. That gap is exactly why we show both numbers side by side.
How much is Micro-X Ltd worth?
The market values Micro-X Ltd at about A$21.1M (market capitalisation, as of Nov 13, 2026). Per share that is A$0.0280; our models calculate a fair value of A$0.0289 per share.
What do the bullish and bearish scenarios say about MX1?
Our models span a range for Micro-X Ltd: cautious scenario A$0.0269, base A$0.0289, optimistic A$0.0308 per share (as of Nov 13, 2026, price A$0.0280). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Micro-X Ltd (MX1)?
Balance-sheet figures for Micro-X Ltd (as of Nov 13, 2026): return on equity −158.0%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is MX1 from its 52-week high?
Micro-X Ltd trades at A$0.0280, about 73% below its 52-week high of A$0.1050 and 100% above the low of A$0.0140 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0289 is for.
Which stocks are comparable to Micro-X Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Micro-X Ltd stock attractive at the current price?
The data as of Nov 13, 2026: price A$0.0280, calculated fair value A$0.0289 (+3%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Micro-X Ltd currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Micro-X Ltd (MX1)?
The closing price on Nov 16, 2026 was A$0.0280. Our estimate is A$0.0289, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Micro-X Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (A$0.0269 to A$0.0308), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Micro-X Ltd

How large is the market capitalisation of Micro-X Ltd (MX1)?
The market capitalisation of Micro-X Ltd is A$21.1M (≈ $14.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Micro-X Ltd (MX1)?
The price-to-sales ratio of Micro-X Ltd is 1.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Micro-X Ltd (MX1)?
Earnings per share at Micro-X Ltd are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Micro-X Ltd (MX1)?
The net margin of Micro-X Ltd is −65.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Micro-X Ltd (MX1)?
The return on equity (ROE) of Micro-X Ltd is −158% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Micro-X Ltd (MX1)?
On an EBIT basis the return on assets of Micro-X Ltd is −64.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Micro-X Ltd (MX1)?
The operating margin of Micro-X Ltd is −312% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Micro-X Ltd (MX1)?
Revenue at Micro-X Ltd is down 32.0% versus a year earlier (3y avg +0.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Micro-X Ltd (MX1) generate?
The free cash flow of Micro-X Ltd is −A$9.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Micro-X Ltd (MX1) carry?
The net debt of Micro-X Ltd is A$3.3M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Micro-X Ltd in the live analysis

One click puts Micro-X Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.